Skip to main content

Advertisement

Table 7 Spearman correlation coefficients between changes in PRO scores and in UC-DAI total scores from baseline to Week 8 in the acute phase

From: Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

  N ρ (95% CI)
SF-12v2
 Physical functioning 532 −0.32 (−0.39, −0.24)
 Role physical 527 −0.44 (− 0.51, − 0.37)
 Bodily pain 522 − 0.41 (− 0.48, − 0.34)
 General health 532 − 0.40 (− 0.47, − 0.33)
 Vitality 523 − 0.35 (− 0.42, − 0.27)
 Social functioning 532 − 0.43 (− 0.50, − 0.36)
 Role emotional 529 − 0.40 (− 0.47, − 0.33)
 Mental health 532 −0.31 (− 0.38, − 0.23)
 PCS 531 − 0.43 (− 0.50, − 0.36)
 MCS 531 −0.37 (− 0.44, − 0.29)
SIBDQ
 Bowel symptoms 442 −0.52 (− 0.58, − 0.45)
 Systemic symptoms 458 −0.33 (− 0.41, − 0.25)
 Emotional function 453 −0.47 (− 0.54, − 0.39)
 Social function 461 −0.52 (− 0.58, − 0.45)
 Total score 430 −0.53 (− 0.59, − 0.46)
WPAI:UC
 Absenteeism 223 0.31 (0.19, 0.42)
 Presenteeism 229 0.36 (0.24, 0.47)
 Overall work impairment 218 0.44 (0.33, 0.54)
 Activity impairment 418 0.48 (0.40, 0.55)
  1. CI confidence interval, MCS mental component summary, PCS physical component summary, PRO patient-reported outcomes, SF-12v2 SF-12v2 Health Survey, SIBDQ Short Inflammatory Bowel Disease Questionnaire, UC-DAI Ulcerative Colitis Disease Activity Index, WPAI:UC Work Productivity and Activity Impairment questionnaire for ulcerative colitis
  2. Week 8 includes early withdrawal visits during the acute phase
  3. All correlation coefficients are statistically different from 0 (all P < 0.001)